Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
14,081
Total Claims
$4.1M
Drug Cost
732
Beneficiaries
$5,632
Cost/Patient
Risk Score Breakdown 18/100
Score components are additive. Read full methodology
Peer Comparison vs. 8,541 Hematology-Oncology providers
-98%
Opioid rate vs peers
0.1% vs 6.3% avg
-59%
Cost per patient vs peers
$5,632 vs $14K avg
+28%
Brand preference vs peers
18.7% vs 14.6% avg
Opioid Prescribing
0.1%
Opioid Rate
17
Opioid Claims
$380
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 2,600 claims · $3.0M
Generic: 11,336 claims · $1.1M
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Lenalidomide | 23 | $422K |
| Ibrutinib | 23 | $387K |
| Omeprazole/Sodium Bicarbonate | 139 | $319K |
| Pomalidomide | 12 | $276K |
| Metformin Hcl | 27 | $228K |
| Bictegrav/Emtricit/Tenofov Ala | 38 | $149K |
| Apixaban | 148 | $99K |
| Sitagliptin Phosphate | 136 | $80K |
| Linaclotide | 124 | $69K |
| Dasatinib | 13 | $67K |
| Abiraterone Acetate | 13 | $48K |
| Lipase/Protease/Amylase | 58 | $45K |
| Empagliflozin | 72 | $44K |
| Sitagliptin Phos/Metformin Hcl | 75 | $42K |
| Rivaroxaban | 53 | $39K |
Prescribing Profile
Patient Profile
73
Avg Age
49%
Female
1.70
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About